Centre d'Information et de documentation du CRA Rhône-Alpes
CRA
Informations pratiques
-
Adresse
Centre d'information et de documentation
du CRA Rhône-Alpes
Centre Hospitalier le Vinatier
bât 211
95, Bd Pinel
69678 Bron CedexHoraires
Lundi au Vendredi
9h00-12h00 13h30-16h00Contact
Tél: +33(0)4 37 91 54 65
Mail
Fax: +33(0)4 37 91 54 37
-
Détail de l'auteur
Auteur Robert C. SMITH |
Documents disponibles écrits par cet auteur (1)
Faire une suggestion Affiner la recherche
Efficacy of Sulforaphane in Treatment of Children with Autism Spectrum Disorder: A Randomized Double-Blind Placebo-Controlled Multi-center Trial / Robert C. SMITH ; Russell H. TOBE ; Jingjing LIN ; Jen ARRIAZA ; Jed W. FAHEY ; Ruiting LIU ; Ying ZENG ; Yanan LIU ; Lian HUANG ; Yidong SHEN ; Yamin LI ; Daomeng CHENG ; Brian CORNBLATT ; John M. DAVIS ; Jingping ZHAO ; Renrong WU ; Hua JIN in Journal of Autism and Developmental Disorders, 54-2 (February 2024)
[article]
Titre : Efficacy of Sulforaphane in Treatment of Children with Autism Spectrum Disorder: A Randomized Double-Blind Placebo-Controlled Multi-center Trial Type de document : Texte imprimé et/ou numérique Auteurs : Robert C. SMITH, Auteur ; Russell H. TOBE, Auteur ; Jingjing LIN, Auteur ; Jen ARRIAZA, Auteur ; Jed W. FAHEY, Auteur ; Ruiting LIU, Auteur ; Ying ZENG, Auteur ; Yanan LIU, Auteur ; Lian HUANG, Auteur ; Yidong SHEN, Auteur ; Yamin LI, Auteur ; Daomeng CHENG, Auteur ; Brian CORNBLATT, Auteur ; John M. DAVIS, Auteur ; Jingping ZHAO, Auteur ; Renrong WU, Auteur ; Hua JIN, Auteur Article en page(s) : p.628-641 Index. décimale : PER Périodiques Résumé : Sulforaphane has been reported to possibly improve core symptoms associated with autism spectrum disorders from mostly small size studies. Here we present results of a larger randomized clinical trial (N?=?108) in China. There were no significant changes in caregiver rated scales between sulforaphane and placebo groups. However, clinician rated scales showed a significant improvement in the sulforaphane group, and one third of participants showed at least a 30% decrease in score by 12 weeks treatment. The effects of sulforaphane were seen across the full range of intelligence and greater in participants over 10 years. Sulforaphane was safe and well-tolerated even for young children. The inconsistent results between caregiver and clinician rated scales suggest more clinical trials are needed to confirm our findings. En ligne : https://doi.org/10.1007/s10803-022-05784-9 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=520
in Journal of Autism and Developmental Disorders > 54-2 (February 2024) . - p.628-641[article] Efficacy of Sulforaphane in Treatment of Children with Autism Spectrum Disorder: A Randomized Double-Blind Placebo-Controlled Multi-center Trial [Texte imprimé et/ou numérique] / Robert C. SMITH, Auteur ; Russell H. TOBE, Auteur ; Jingjing LIN, Auteur ; Jen ARRIAZA, Auteur ; Jed W. FAHEY, Auteur ; Ruiting LIU, Auteur ; Ying ZENG, Auteur ; Yanan LIU, Auteur ; Lian HUANG, Auteur ; Yidong SHEN, Auteur ; Yamin LI, Auteur ; Daomeng CHENG, Auteur ; Brian CORNBLATT, Auteur ; John M. DAVIS, Auteur ; Jingping ZHAO, Auteur ; Renrong WU, Auteur ; Hua JIN, Auteur . - p.628-641.
in Journal of Autism and Developmental Disorders > 54-2 (February 2024) . - p.628-641
Index. décimale : PER Périodiques Résumé : Sulforaphane has been reported to possibly improve core symptoms associated with autism spectrum disorders from mostly small size studies. Here we present results of a larger randomized clinical trial (N?=?108) in China. There were no significant changes in caregiver rated scales between sulforaphane and placebo groups. However, clinician rated scales showed a significant improvement in the sulforaphane group, and one third of participants showed at least a 30% decrease in score by 12 weeks treatment. The effects of sulforaphane were seen across the full range of intelligence and greater in participants over 10 years. Sulforaphane was safe and well-tolerated even for young children. The inconsistent results between caregiver and clinician rated scales suggest more clinical trials are needed to confirm our findings. En ligne : https://doi.org/10.1007/s10803-022-05784-9 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=520